Antiphospholipid Antibodies and the Antiphospholipid Syndrome I: Pathogenesis, Clinical Features, Diagnosis, and Management

Semin Thromb Hemost 2008; 34(3): 213-218
DOI: 10.1055/s-0028-1082264

PREFACE

Richard C.W Wong¹ , Emmanuel J. Favaloro²

¹Division of Immunology, Pathology Queensland (Central Laboratory), Royal Brisbane and Womens Hospital, Herston, Queensland, Australia
²Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, SWAHS, Westmead, NSW, Australia

REFERENCES

1 Harris E N, Gharavi A E, Boey M L et al.. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983; 2 1211-1214
2 Wilson W A. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am. 2001; 27 499-505
3 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4 295-306
4 Favaloro E J, Wong R C. Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing. Semin Thromb Hemost. 2008; 34 , (in press)
5 Erkan D, Harrison M J, Levy R et al.. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007; 56 2382-2391
6 Janardhan V, Wolf P A, Kase C S et al.. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke. 2004; 35 736-741
7 Muñoz-Rodriguez F J, Font J, Cervera R et al.. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999; 29 182-190
8 Asherson R A. The catastrophic antiphospholipid syndrome. J Rheumatol. 1992; 19 508-512